Following a successful global search by The RSA Group, Engitix Ltd has appointed Gino Van Heeke as Chief Scientific Officer. A pioneer of their field, Engitix develops tissue and disease specific human extracellular matrix scaffolds, vital tools in the acceleration and improvement of the drug discovery process.
Dr Van Heeke joins Engitix Ltd with over 20 years’ experience across the fields of biologics and small molecule drug discovery and drug development. For the past five years he has held the position of Senior Director of Discovery and Early Development at Ablynx, where he oversaw more than 30 drug discovery projects. Prior to this, he held a series of senior positions at Novartis, developing the company’s respiratory franchise.
Dr Andy Theodorou, Senior Consultant at The RSA Group, commented, “the careful candidate due diligence of our team throughout the extensive global search was vital to the successful appointment of Dr Van Heeke.”
Dr Giuseppe Mazza, Co-Founder and CEO of Engitix Ltd, added, “The RSA Group provided excellent advice and support throughout the entire decision-making process. We are delighted with the result and to look forward to working with Dr Van Heeke.”